Table of Contents
Volume 1 | Supplement 1
Publication Date: November 2000- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Introduction | ||
S7 |
Two Novel Therapies for the Treatment of Cutaneous T-Cell Lymphoma C. Frederick LeMaistre |
|
Contributions | ||
S9-S14 |
An Oncologist’s Approach to Therapy for Cutaneous T-Cell Lymphoma Francine M. Foss |
|
S15-S20 |
Treatment of Cutaneous T-Cell Lymphoma from a Dermatologist’s Perspective Madeleine Duvic |
|
S21-S25 |
Cutaneous T-Cell Lymphomas: Prognosis and Quality-of-Life Issues Reinhard Dummer, Monika Hess-Schmid, Günter Burg |
|
S27-S31 |
DAB389IL-2 (Denileukin Diftitox, ONTAK): A New Fusion Protein Technology Francine M. Foss |
|
S33-S36 |
DAB389IL-2 (Denileukin Diftitox, ONTAK): Review of Clinical Trials to Date Timothy M. Kuzel |
|
S37-S40 |
DAB389IL-2 (Denileukin Diftitox, ONTAK): Other Potential Applications C. Frederick LeMaistre |
|
S41-S44 |
Historical Perspective on the Use of Retinoids in Cutaneous T-Cell Lymphoma (CTCL) Günter Burg, Reinhard Dummer |
|
S45-S49 |
The Treatment of Cutaneous T-Cell Lymphoma with a Novel Retinoid Peter Heald |
|
S51-S55 |
Bexarotene and DAB389IL-2 (Denileukin Diftitox, ONTAK) in Treatment of Cutaneous T-Cell Lymphomas: Algorithms Madeleine Duvic |
|